Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial-Reference-Cited by-同舟云学术

Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial

Published:2023-10 Issue: Volume:192 Page:113258
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Fizazi Karim,Shore Neal D.,Smith Matthew,Ramos Rodrigo,Jones Robert,Niegisch Günter^ORCID,Vjaters Egils,Wang Yuan,Srinivasan Shankar,Sarapohja Toni^ORCID,Verholen Frank

Funder

OMRON Corporation

Bayer HealthCare

Bayer AG

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Managing nonmetastatic castration-resistant prostate cancer;Mateo;Eur Urol,2019

2. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors;Saad;Prostate Cancer Prostatic Dis,2021

3. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients;Boyle;Eur J Cancer,2019

4. Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers;Ramsdale;J Geriatr Oncol,2018

5. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial;Shore;Target Oncol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies;Critical Reviews in Oncology/Hematology;2024-08

2. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

3. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol;European Urology Oncology;2024-05